SCHEMBL308530

SCHEMBL308530

O=C(O)C1CCN(Nc2ccnc(-c3ccccn3)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
KDM4E B2RXH2 4/20 0.46
KDM6B O15054 1/20 0.46
KDM4A O75164 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4C Q9H3R0 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
CYP2C19 P33261 1/20 0.46
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ACVRL1 P37023 1/20 0.40
CYP46A1 Q9Y6A2 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
ALDH1A1 P00352 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
MALT1 Q9UDY8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099032 0.78 KDM4E (0.56) L3MBTL1KDM4EKDM6BKDM4AKDM5C
SCHEMBL7735744 0.78 L3MBTL1 (0.49) L3MBTL1KDM4ECYP2C19RAB9ANPC1
SCHEMBL21552512 0.70 KDM4E (0.56) L3MBTL1KDM4ECYP2C19CYP46A1NEK2
SCHEMBL4847559 0.70 NEK2 (0.51) L3MBTL1KDM4ECYP2C19GSK3BDYRK1A
SCHEMBL2274636 0.68 KDM4E (0.66) L3MBTL1KDM4ECYP2C19LMNASMN1; SMN2
SCHEMBL8136030 0.67 KDM4E (0.51) L3MBTL1KDM4EKDM6BKDM4AKDM5C
SCHEMBL1299138 0.67 ALDH1A1 (0.60) KDM4ERAB9ANPC1LMNASMN1; SMN2
SCHEMBL3259257 0.65 HPGD (0.63) KDM4ERAB9ANPC1LMNASMN1; SMN2
Dipyridyl SCHEMBL18601618 0.65 KDM4E (0.74) L3MBTL1KDM4EKDM6BKDM4AKDM5C
Dipyridyl SCHEMBL2792069 0.65 KDM4E (0.74) L3MBTL1KDM4EKDM6BKDM4AKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10219730-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2019-03-05 US disclosed
US-20160296147-A1 Redox Polymers THERASENSE, INC. 2016-10-13 US disclosed
US-9320467-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2016-04-26 US disclosed
US-20140364710-A1 Redox Polymers THERASENSE, INC. 2014-12-11 US disclosed
US-8828204-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2014-09-09 US disclosed
US-8795490-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2014-08-05 US disclosed
US-8512534-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2013-08-20 US disclosed
US-8444834-B2 Redox polymers for use in analyte monitoring ABBOTT DIABETES CARE INC. (US) 2013-05-21 US disclosed
US-8268143-B2 Oxygen-effect free analyte sensor ABBOTT DIABETES CARE INC. (US) 2012-09-18 US disclosed
US-20120132525-A1 REDOX POLYMERS FOR USE IN ANALYTE MONITORING ABBOTT DIABETES CARE INC. 2012-05-31 US disclosed
US-20100288634-A1 Transition Metal Complexes with Bidentate Ligand Having an Imidazole Ring ABBOTT DIABETES CARE INC. 2010-11-18 US disclosed
US-20090145757-A1 Redox Polymers ABBOTT DIABETES CARE INC. 2009-06-11 US disclosed
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR ABBOTT DIABETES CARE INC. 2009-04-16 US disclosed
US-20070007132-A1 Transition metal complexes with bidentate ligand having an imidazole ring ABBOTT DIABETES CARE INC. 2007-01-11 US disclosed
US-7090756-B2 Controller for redox system THERASENSE INC. (US) 2006-08-15 US disclosed
EP-1230249-B1 TRANSITION METAL COMPLEXES WITH BIDENTATE LIGAND HAVING AN IMIDAZOLE RING THERASENSE INC (US) 2004-06-02 EP disclosed
US-20040040840-A1 Controller for redox system THERASENSE, INC. 2004-03-04 US disclosed
US-6605201-B1 Charge transfer compounds comprising osmium compounds coupled to polymers, used as biosensors THERASENSE, INC. 2003-08-12 US disclosed
EP-1230249-A1 TRANSITION METAL COMPLEXES WITH BIDENTATE LIGAND HAVING AN IMIDAZOLE RING Therasense, Inc. (US) 2002-08-14 EP disclosed
WO-2001036430-A1 TRANSITION METAL COMPLEXES WITH BIDENTATE LIGAND HAVING AN IMIDAZOLE RING THERASENSE, INC. (US) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR LPO, TXN2, PRDX5 L3MBTL1 3476/4885KDM4E 1493/4885KDM6B 1705/4885
US-20040040840-A1 Controller for redox system OTC, ME3, PPOX L3MBTL1 3745/4885KDM4E 1472/4885KDM6B 2345/4885
US-10219730-B2 Redox polymers PPOX, OTC, ME3 L3MBTL1 3698/4885KDM4E 2030/4885KDM6B 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.